Business
Shareholders Update
VANCOUVER, BC / ACCESSWIRE / August 21, 2019 / ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY) (&#...
About this update from Else Nutrition Holdings Inc
[{"type":"text","content":"Shareholders UpdateVANCOUVER, BC / ACCESSWIRE / August 21, 2019 / ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY) (“BABY” or the “Company”), a company focused on developing and marketing a real alternative to dairy-based baby nutrition, is pleased to provide the following update letter to shareholders.Product Highlights Preparing mass production and manufacturing scale-up protocols for our products.Preparation of healthy Toddler snacks launch in the U.S. market.Preparing digital marketing and social influencer campaigns.Key Recruits Highlights Recruited Dr. Fabiana Bar-Yoseph, M.Sc., Ph.D., ex Infant Nutrition R&D Director at Enzymotec (ENZY), as Director of Clinical Development, Regulatory and Scientific Affairs to lead FDA Certification for infants (0-12 months).Recruited Mr. Asher Waidberg, B.Sc. in Bio-Chemical Engineering and ex Infant Nutrition Development Process Manager at Enzymotec (ENZY), to lead Else New Product Development.Recruited Barak Orenstein, ex Sodastream, L’Oréal, Nestle and Evian water as Director of Digital Marketing.Recruited Mr. Shay Shamir, ex Atlantium Technologies clean tech and E&Y, as CFO and Company Secretary.Dear Shareholders,We began our journey this past June, and I am pleased to provide you with this update:Clinical ResearchObtaining United States Food and Drug Administration (U.S. FDA) certification for infants (0-12 months old) is a mission critical task for Else Nutrition, as it represents a $90 Billion market; therefore we have added Fabiana Bar-Yoseph, M.Sc., Ph.D., to the Else team as Director of Clinical Development, Regulatory and Scientific Affairs.Ms. Bar-Yoseph holds both a PH.D. and a Master’s degree in Medical Science from the esteemed Technion, Israel Institute of Technology. She joins Else Nutrition with the precise experience and knowledge required, coupled with ardent passion for our sector and products. Fabiana has nearly 10 years of expertise as a former Clinical Development Director and Infant Nutrition R&D Director at Enzymotec (enzymotec.com), a public Israeli company (ENZY), acquired in 2017 by Frutarom (FRUT,), and subsequently acquired in October 2018 by International Flavors and Fragrances (IFF).Ms. Bar-Yoseph has already commenced preparation for the clinical study process, identifying suitable partners, experts and...